{
    "info": {
        "nct_id": "NCT06146257",
        "official_title": "A First-in-human, Phase 1, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes",
        "inclusion_criteria": "* Participants is ≥ 18 years of age at the time of signing the Informed Consent Form (ICF).\n* Participants must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.\n* Participants are willing and able to adhere to the study visit schedule and other protocol requirements.\n* Participants with histologically or cytologically confirmed AML including de novo AML or secondary AML transformed from MDS according to 2022 World Health Organization (WHO) criteria classification, or with histologically or cytologically confirmed HR-MDS.\n* R/R AML and R/R HR-MDS who have failed or are ineligible for all available therapies which may provide clinical benefit.\n* Participants must have the following screening laboratory values:\n\n  * Total white blood cell count (WBC) < 25 x 10^9/L prior to the first dose of the study drug.\n  * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × upper limit of normal (ULN), unless considered due to extensive leukemic liver involvement, in which case AST and ALT can be ≤ 5.0 x ULN.\n  * Serum total bilirubin ≤ 1.5 x ULN, unless considered due to Gilbert's syndrome, in which case serum total bilirubin < 3 x ULN.\n  * Estimated serum creatinine clearance of ≥ 60 mL/min using the Cockcroft-Gault equation. Measured creatinine clearance from a 24-hour urine collection is acceptable if clinically indicated.\n  * International normalized ratio (INR) ≤ 1.5 x ULN and active partial thromboplastin time (aPTT) ≤ 1.5 x ULN.\n* Life expectancy ≥ 12 weeks.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.\n* Female Participants of child-bearing potential must have a negative serum or urine pregnancy test at screening and at pre-dose on Cycle 1 Day 1 (C1D1).\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Participants with acute promyelocytic leukemia (APML).\n* Participants with known leukemic involvement in central nervous system (CNS).\n* Receipt of anticancer medications/therapies within 5 half-lives or 28 days before the first administration of the study drug.\n* Participants with unresolved clinically significant non-hematologic toxicities of ≥ Grade 2 AE from prior therapies with exception of residual alopecia.\n* Participants with chronic graft versus host disease (GVHD) requiring systemic immunosuppressive therapy.\n* Participants with active malignancies other than AML or MDS.\n* Participants who have undergone major surgery ≤ 4 weeks prior to the first dose of the study drug.\n* Participants with immediately life-threatening, severe complications of leukemia such as disseminated/uncontrolled infection (bacterial and/or fungal), uncontrolled bleeding, and/or uncontrolled disseminated intravascular coagulation.\n* Participants with known chronic, active infection of hepatitis B virus (HBV), hepatitis C virus C (HCV), human immunodeficiency virus (HIV).\n* Participants unable to swallow oral medications, or Participants with clinically significant diarrhea, vomiting or malabsorption felt limited absorption of orally administered medications.\n* Participants with any other significant medical conditions, any other conditions, laboratory abnormality, or psychiatric illness which place the Participants at unacceptable risk if he/she were to participate in the study or that would hamper the Participants understanding of the study, or would prevent the Participant from complying with the study.\n* Medications or supplements that are known to be strong and moderate inhibitors or inducers of CYP450 isozyme 3A4 (CYP3A4) and/or P-glycoprotein (P-gp), or strong inhibitors or inducers of CYP450 isozyme 2C8 (CYP2C8) within 14 days or 5 half-lives, whichever is shorter, before the first dose of study drug.\n* Pregnant or lactating women.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Participants is ≥ 18 years of age at the time of signing the Informed Consent Form (ICF).",
            "criterions": [
                {
                    "exact_snippets": "Participants is ≥ 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total white blood cell count (WBC) < 25 x 10^9/L prior to the first dose of the study drug.",
            "criterions": [
                {
                    "exact_snippets": "Total white blood cell count (WBC) < 25 x 10^9/L prior to the first dose of the study drug.",
                    "criterion": "total white blood cell count (WBC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 25,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy ≥ 12 weeks.",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy ≥ 12 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum total bilirubin ≤ 1.5 x ULN, unless considered due to Gilbert's syndrome, in which case serum total bilirubin < 3 x ULN.",
            "criterions": [
                {
                    "exact_snippets": "Serum total bilirubin ≤ 1.5 x ULN",
                    "criterion": "serum total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless considered due to Gilbert's syndrome, in which case serum total bilirubin < 3 x ULN",
                    "criterion": "serum total bilirubin in patients with Gilbert's syndrome",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.",
            "criterions": [
                {
                    "exact_snippets": "Participants must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.",
                    "criterion": "informed consent form (ICF)",
                    "requirements": [
                        {
                            "requirement_type": "comprehension",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "voluntary signature",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to any study-related assessments/procedures"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants are willing and able to adhere to the study visit schedule and other protocol requirements.",
            "criterions": [
                {
                    "exact_snippets": "Participants are willing ... to adhere to the study visit schedule",
                    "criterion": "adherence to study visit schedule",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants are ... able to adhere to the study visit schedule",
                    "criterion": "adherence to study visit schedule",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants are willing and able to adhere to ... other protocol requirements",
                    "criterion": "adherence to other protocol requirements",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with histologically or cytologically confirmed AML including de novo AML or secondary AML transformed from MDS according to 2022 World Health Organization (WHO) criteria classification, or with histologically or cytologically confirmed HR-MDS.",
            "criterions": [
                {
                    "exact_snippets": "histologically or cytologically confirmed AML",
                    "criterion": "acute myeloid leukemia (AML)",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histological",
                                "cytological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "de novo AML or secondary AML transformed from MDS",
                    "criterion": "type of AML",
                    "requirements": [
                        {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "de novo AML",
                                "secondary AML transformed from MDS"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "according to 2022 World Health Organization (WHO) criteria classification",
                    "criterion": "diagnosis classification system",
                    "requirements": [
                        {
                            "requirement_type": "classification system",
                            "expected_value": "2022 WHO criteria"
                        }
                    ]
                },
                {
                    "exact_snippets": "histologically or cytologically confirmed HR-MDS",
                    "criterion": "high-risk myelodysplastic syndrome (HR-MDS)",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histological",
                                "cytological"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* International normalized ratio (INR) ≤ 1.5 x ULN and active partial thromboplastin time (aPTT) ≤ 1.5 x ULN.",
            "criterions": [
                {
                    "exact_snippets": "International normalized ratio (INR) ≤ 1.5 x ULN",
                    "criterion": "International normalized ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "active partial thromboplastin time (aPTT) ≤ 1.5 x ULN",
                    "criterion": "active partial thromboplastin time (aPTT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Estimated serum creatinine clearance of ≥ 60 mL/min using the Cockcroft-Gault equation. Measured creatinine clearance from a 24-hour urine collection is acceptable if clinically indicated.",
            "criterions": [
                {
                    "exact_snippets": "Estimated serum creatinine clearance of ≥ 60 mL/min using the Cockcroft-Gault equation",
                    "criterion": "serum creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "estimation method",
                            "expected_value": "Cockcroft-Gault equation"
                        },
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "mL/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Measured creatinine clearance from a 24-hour urine collection is acceptable if clinically indicated",
                    "criterion": "creatinine clearance measurement method",
                    "requirements": [
                        {
                            "requirement_type": "measurement method",
                            "expected_value": "24-hour urine collection"
                        },
                        {
                            "requirement_type": "acceptability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have the following screening laboratory values:",
            "criterions": [
                {
                    "exact_snippets": "screening laboratory values",
                    "criterion": "screening laboratory values",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female Participants of child-bearing potential must have a negative serum or urine pregnancy test at screening and at pre-dose on Cycle 1 Day 1 (C1D1).",
            "criterions": [
                {
                    "exact_snippets": "Female Participants of child-bearing potential",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "child-bearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative serum or urine pregnancy test at screening and at pre-dose on Cycle 1 Day 1 (C1D1)",
                    "criterion": "pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "test type",
                            "expected_value": [
                                "serum",
                                "urine"
                            ]
                        },
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timepoint",
                            "expected_value": [
                                "screening",
                                "pre-dose on Cycle 1 Day 1 (C1D1)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* R/R AML and R/R HR-MDS who have failed or are ineligible for all available therapies which may provide clinical benefit.",
            "criterions": [
                {
                    "exact_snippets": "R/R AML",
                    "criterion": "relapsed or refractory acute myeloid leukemia (AML)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "R/R HR-MDS",
                    "criterion": "relapsed or refractory high-risk myelodysplastic syndrome (HR-MDS)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "who have failed or are ineligible for all available therapies which may provide clinical benefit",
                    "criterion": "prior therapies providing clinical benefit",
                    "requirements": [
                        {
                            "requirement_type": "failure of all available therapies",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ineligibility for all available therapies",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × upper limit of normal (ULN), unless considered due to extensive leukemic liver involvement, in which case AST and ALT can be ≤ 5.0 x ULN.",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) ... ≤ 3.0 × upper limit of normal (ULN), unless considered due to extensive leukemic liver involvement, in which case AST ... can be ≤ 5.0 x ULN.",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3.0,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (if extensive leukemic liver involvement)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5.0,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) ... ≤ 3.0 × upper limit of normal (ULN), unless considered due to extensive leukemic liver involvement, in which case ... ALT can be ≤ 5.0 x ULN.",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3.0,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (if extensive leukemic liver involvement)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5.0,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Participants with acute promyelocytic leukemia (APML).",
            "criterions": [
                {
                    "exact_snippets": "Participants with acute promyelocytic leukemia (APML)",
                    "criterion": "acute promyelocytic leukemia (APML)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with known chronic, active infection of hepatitis B virus (HBV), hepatitis C virus C (HCV), human immunodeficiency virus (HIV).",
            "criterions": [
                {
                    "exact_snippets": "known chronic, active infection of hepatitis B virus (HBV)",
                    "criterion": "hepatitis B virus (HBV) infection",
                    "requirements": [
                        {
                            "requirement_type": "chronic active infection",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known chronic, active infection of ... hepatitis C virus C (HCV)",
                    "criterion": "hepatitis C virus (HCV) infection",
                    "requirements": [
                        {
                            "requirement_type": "chronic active infection",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known chronic, active infection of ... human immunodeficiency virus (HIV)",
                    "criterion": "human immunodeficiency virus (HIV) infection",
                    "requirements": [
                        {
                            "requirement_type": "chronic active infection",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with known leukemic involvement in central nervous system (CNS).",
            "criterions": [
                {
                    "exact_snippets": "known leukemic involvement in central nervous system (CNS)",
                    "criterion": "leukemic involvement in central nervous system (CNS)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant or lactating women.",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating women",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with unresolved clinically significant non-hematologic toxicities of ≥ Grade 2 AE from prior therapies with exception of residual alopecia.",
            "criterions": [
                {
                    "exact_snippets": "unresolved clinically significant non-hematologic toxicities of ≥ Grade 2 AE from prior therapies",
                    "criterion": "non-hematologic toxicities from prior therapies",
                    "requirements": [
                        {
                            "requirement_type": "resolution",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "Grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "exception of residual alopecia",
                    "criterion": "residual alopecia",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with active malignancies other than AML or MDS.",
            "criterions": [
                {
                    "exact_snippets": "active malignancies other than AML or MDS",
                    "criterion": "active malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": {
                                "operator": "!=",
                                "value": 1,
                                "unit": "AML or MDS"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants unable to swallow oral medications, or Participants with clinically significant diarrhea, vomiting or malabsorption felt limited absorption of orally administered medications.",
            "criterions": [
                {
                    "exact_snippets": "Participants unable to swallow oral medications",
                    "criterion": "ability to swallow oral medications",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant diarrhea",
                    "criterion": "diarrhea",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "clinically significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "vomiting",
                    "criterion": "vomiting",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "malabsorption felt limited absorption of orally administered medications",
                    "criterion": "malabsorption affecting absorption of oral medications",
                    "requirements": [
                        {
                            "requirement_type": "effect on absorption of oral medications",
                            "expected_value": "limited absorption"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with chronic graft versus host disease (GVHD) requiring systemic immunosuppressive therapy.",
            "criterions": [
                {
                    "exact_snippets": "chronic graft versus host disease (GVHD)",
                    "criterion": "chronic graft versus host disease (GVHD)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring systemic immunosuppressive therapy",
                    "criterion": "systemic immunosuppressive therapy",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": "required"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Medications or supplements that are known to be strong and moderate inhibitors or inducers of CYP450 isozyme 3A4 (CYP3A4) and/or P-glycoprotein (P-gp), or strong inhibitors or inducers of CYP450 isozyme 2C8 (CYP2C8) within 14 days or 5 half-lives, whichever is shorter, before the first dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Medications or supplements that are known to be strong and moderate inhibitors or inducers of CYP450 isozyme 3A4 (CYP3A4)",
                    "criterion": "concomitant medications or supplements (CYP3A4 inhibitors/inducers)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "inhibition/induction strength",
                            "expected_value": [
                                "strong",
                                "moderate"
                            ]
                        },
                        {
                            "requirement_type": "enzyme target",
                            "expected_value": "CYP3A4"
                        }
                    ]
                },
                {
                    "exact_snippets": "Medications or supplements that are known to be ... strong inhibitors or inducers of CYP450 isozyme 2C8 (CYP2C8)",
                    "criterion": "concomitant medications or supplements (CYP2C8 inhibitors/inducers)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "inhibition/induction strength",
                            "expected_value": "strong"
                        },
                        {
                            "requirement_type": "enzyme target",
                            "expected_value": "CYP2C8"
                        }
                    ]
                },
                {
                    "exact_snippets": "Medications or supplements that are known to be ... inhibitors or inducers of ... P-glycoprotein (P-gp)",
                    "criterion": "concomitant medications or supplements (P-gp inhibitors/inducers)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "enzyme target",
                            "expected_value": "P-gp"
                        }
                    ]
                },
                {
                    "exact_snippets": "within 14 days or 5 half-lives, whichever is shorter, before the first dose of study drug",
                    "criterion": "timing of medication/supplement use",
                    "requirements": [
                        {
                            "requirement_type": "time window before first dose",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 14,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants who have undergone major surgery ≤ 4 weeks prior to the first dose of the study drug.",
            "criterions": [
                {
                    "exact_snippets": "undergone major surgery ≤ 4 weeks prior to the first dose of the study drug",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with immediately life-threatening, severe complications of leukemia such as disseminated/uncontrolled infection (bacterial and/or fungal), uncontrolled bleeding, and/or uncontrolled disseminated intravascular coagulation.",
            "criterions": [
                {
                    "exact_snippets": "immediately life-threatening, severe complications of leukemia",
                    "criterion": "complications of leukemia",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "immediately life-threatening or severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "disseminated/uncontrolled infection (bacterial and/or fungal)",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "disseminated or uncontrolled"
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "bacterial",
                                "fungal"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled bleeding",
                    "criterion": "bleeding",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled disseminated intravascular coagulation",
                    "criterion": "disseminated intravascular coagulation",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Receipt of anticancer medications/therapies within 5 half-lives or 28 days before the first administration of the study drug.",
            "criterions": [
                {
                    "exact_snippets": "Receipt of anticancer medications/therapies within 5 half-lives or 28 days before the first administration of the study drug.",
                    "criterion": "receipt of anticancer medications/therapies",
                    "requirements": [
                        {
                            "requirement_type": "time since last receipt",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 5,
                                        "unit": "half-lives"
                                    },
                                    {
                                        "operator": ">",
                                        "value": 28,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with any other significant medical conditions, any other conditions, laboratory abnormality, or psychiatric illness which place the Participants at unacceptable risk if he/she were to participate in the study or that would hamper the Participants understanding of the study, or would prevent the Participant from complying with the study.",
            "criterions": [
                {
                    "exact_snippets": "any other significant medical conditions ... place the Participants at unacceptable risk if he/she were to participate in the study",
                    "criterion": "significant medical conditions",
                    "requirements": [
                        {
                            "requirement_type": "risk to participant",
                            "expected_value": "unacceptable risk if participating in the study"
                        }
                    ]
                },
                {
                    "exact_snippets": "any other conditions ... place the Participants at unacceptable risk if he/she were to participate in the study",
                    "criterion": "other conditions",
                    "requirements": [
                        {
                            "requirement_type": "risk to participant",
                            "expected_value": "unacceptable risk if participating in the study"
                        }
                    ]
                },
                {
                    "exact_snippets": "laboratory abnormality ... place the Participants at unacceptable risk if he/she were to participate in the study",
                    "criterion": "laboratory abnormality",
                    "requirements": [
                        {
                            "requirement_type": "risk to participant",
                            "expected_value": "unacceptable risk if participating in the study"
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric illness ... place the Participants at unacceptable risk if he/she were to participate in the study",
                    "criterion": "psychiatric illness",
                    "requirements": [
                        {
                            "requirement_type": "risk to participant",
                            "expected_value": "unacceptable risk if participating in the study"
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric illness ... would hamper the Participants understanding of the study",
                    "criterion": "psychiatric illness",
                    "requirements": [
                        {
                            "requirement_type": "impact on understanding",
                            "expected_value": "would hamper understanding of the study"
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric illness ... would prevent the Participant from complying with the study",
                    "criterion": "psychiatric illness",
                    "requirements": [
                        {
                            "requirement_type": "impact on compliance",
                            "expected_value": "would prevent compliance with the study"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}